Vandetanib targets RET, vascular endothelial growth factor receptor-2 and -3 (VEGFR2/3), and epidermal growth factor receptor (EGFR) signaling that contribute to the growth and invasiveness of MTC. Here, RET is linked to medullary thyroid gland carcinoma.